We scan new podcasts and send you the top 5 insights daily.
Dr Sands says that as IMforte data matured, the tails of the progression-free and overall survival curves came together. That convergence suggests the early hazard ratios may overstate how durable the lurbinectedin maintenance benefit is over time for extensive-stage SCLC in the first-line maintenance setting.
Dr Sands says no one expects durvalumab to work differently from atezolizumab when paired with lurbinectedin. Even a positive durvalumab trial that merely matches atezolizumab data would still not answer the larger question of whether lurbinectedin belongs in first-line maintenance for extensive-stage SCLC at all.
Dr Sands says IMforte’s lower neutropenia rate versus the prior second-line lurbinectedin trial likely reflects allowed primary G-CSF prophylaxis, not an intrinsically safer regimen. The combination still raised anemia, neutropenia, and thrombocytopenia when added to atezolizumab maintenance, so toxicity remains a real tradeoff for patients.
While lurbinectedin initially improves survival outcomes as maintenance therapy, long-term data shows the survival curves eventually converge. Experts interpret this to mean the drug provides a temporary, additive chemotherapy-like effect rather than a true synergy with immunotherapy that would produce a durable response and separate the "tails of the curves."
The IMFORTE trial saw a 25% attrition rate between induction and randomization for maintenance therapy. This reflects the clinical reality that a significant portion of patients are too debilitated by initial chemo-IO to be candidates for intensified maintenance, making immunotherapy alone a reasonable alternative for them.
Dr. Carbone argues that traditional metrics like median survival or response rate are less relevant for immunotherapies. The true measure of success is the percentage of patients alive at five or six years—the "tail of the curve"—as this indicates a durable, potentially curative, response.
Dr Sen says the biggest challenge to lurbinectedin maintenance is Delphi 305, which tests terlatumab plus durvalumab against durvalumab alone after induction chemoimmunotherapy. Its phase 3 results could reshape first-line maintenance before the durvalumab-lurbinectedin question matters, so it is the single key readout to watch.
In the MFORTE trial, the survival curves for the lurbinectedin-atezolizumab arm eventually converge with the atezolizumab-only arm. This indicates the combination provides an additive benefit (delaying progression) rather than true synergy, which would have created a more durable, long-term survival advantage.
The observed interim overall survival hazard ratio of 0.76 is encouraging but not definitive. Experts caution that such early signals often represent the peak benefit, which can diminish over time as control group patients receive other effective treatments post-progression, making final statistical significance uncertain.
The progression-free survival (PFS) curves for Belzutifan regimens consistently overlap with controls for 6-8 months before separating. This signature “Belzutifan effect,” seen across multiple trials, suggests the drug provides durable, long-term disease control for a subset of patients rather than immediate, broad efficacy, hinting at a distinct biological mechanism.
Dr Sands says Lagoon’s second-line control arm had median overall survival above 10 months, which was surprising. Lurbinectedin’s initial FDA approval rested on a single-arm study with 9.3-month median survival, so today’s second-line comparator sets a higher bar than the old benchmark for relapsed disease.